Notes

MiMedx Announces Comprehensive Board Refreshment Plan in Cooperation with Prescience Point
MARIETTA, Ga., May well 30, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC LILAC: MDXG) ("MiMedx" or the "Company"), an sector leader in superior wound care in addition to an emerging healing biologics company, right now announced how the Industry’s board of directors (the "Board") offers adopted a comprehensive strategy to refresh the particular composition of the particular Board. The approach was developed with the Board in co-operation with one of the Company's largest shareholders, Prescience Level Capital Management LLC ("Prescience Point"), in addition to follows the completion of the Taxation Committee's independent investigation into alleged wrongdoing by the earlier senior management staff along with the engagement of BDO USA, LLP as being the Company's new independent registered open accounting firm.

Under the plan, six new directors, which includes MiMedx's new CEO, Timothy R. Wright, would be included with the Board. Consequently, Class II and Class III in the Board would consist entirely of fresh directors after typically the Company's 2019 annual meeting of investors. The refreshment program includes the appointment of three of Prescience Point's candidates, including M. Kathleen Behrens Wilsey, Ph. D. because the brand-new Chairwoman with the Panel, as well because K. Todd Newton, who may be expected to become the Chairman of the Audit Committee after the Company's 2019 gross annual meeting of shareholders.

"The MiMedx Plank and the present senior leadership team have been functioning tirelessly to handle the fallout by the actions of the prior senior supervision team and obtain the business back upon track, " explained Charles R. Evans, Chairman in the Table. "Now that we get built substantial progress about these fronts, it is time to begin the Board transition and refreshment process. We are thrilled to have performed collaboratively with Supposition Indicate identify in addition to add new directors who bring excellent experience and monitor records to MiMedx. With the Exam Committee's investigation comprehensive and a strategy to refresh the Board set up, typically the Company is now able to focus on its future in addition to enhance its company, for the gain of all stakeholders. "

"We desired the comprehensive intend to refresh the Plank, and we seem forward to MiMedx's future under new leadership. We are pleased that our cooperation has resulted in a reconstituted Board, with the particular addition of half a dozen new directors with valuable industry knowledge, relationships and reputational capital, " explained Eiad Asbahi, Originator and Managing Spouse of Prescience Point. "We invested throughout MiMedx because many of us believe the organization provides immense potential as a leader throughout advanced wound care and therapeutic biologics. We believe MiMedx is on typically the path to uncover substantial shareholder price and secure the thriving future for the Company. very well

Under the refreshment plan, Prescience Point nominee M. Kathleen Behrens Wilsey, Ph. D. will get appointed or nominated for election to be able to the Board plus is expected to be named the new Chairwoman associated with the Board. Dr . Behrens Wilsey is currently the Chairwoman involving Sarepta Therapeutics, Incorporation. (SRPT), a multi-billion-dollar medical research and even drug development organization targeted on the finding and development regarding unique RNA-targeted therapeutics for the take care of rare neuromuscular diseases. Dr. Behrens Wilsey previously served within the boards of Amylin Pharmaceuticals, Inc. (formerly AMLN) and Abgenix, Inc. (formerly ABGX).

In addition to be able to Dr. Behrens Wilsey, the Board can also appoint, or perhaps nominate for political election to the Board, Richard J. Barry, James L. Bierman, K. Todd Newton, Mr. Wright in addition to another director who will be employed by the Company and Prescience Level. Complete biographies with the anticipated new owners appear at the end of the click release.

The Company expects to file its preliminary proxy materials for the 2018 Annual Meeting right now. The Board promotes shareholders to hold back to be able to receive the Company's proxy materials in addition to the Company's GLOWING BLUE proxy card prior to voting.

Sidley Downtown LLP is acting as legal consultant to MiMedx. Olshan Frome Wolosky LLP is acting while legal advisor to Prescience Point.

Regarding Richard J. Craig
Mr. Barry offers served as a representative of Elcelyx Therapeutics, Inc., a personal pharmaceutical drug company, since Feb 2013 and has offered as a Handling Member of GSM Fund, LLC, the fund established with regard to the sole goal of investing found in Elcelyx Therapeutics, given that February 2013. Earlier in his career, he was a starting up member of Eastbourne Capital Management LLC, a large equity hedge fund trading in a number of industrial sectors, including medical, in addition to served as the Handling General Partner in addition to Portfolio Manager from 1999 to it is close in 2010. Before to that, he was a Portfolio Manager and Managing Overseer of Robertson Stephens Investment Management, an investment company, from 95 until 1999. Ahead of that, Mr. Craig spent over tough luck years in numerous roles in institutional equity and purchase management firms, which include Lazard Freres, Legg Mason and Merrill Lynch. Mr. Barry has served as a director of Sarepta Therapeutics, Incorporation. (SRPT), a genetic medicine company, considering that June 2015, and even he has recently been a Partner in addition to Advisory Board associate of the Hillcrest Padres since 2009. Mr. Barry previously served as a new director of Cluster Wireless, LLC, a new software company, through 2011 until 2014, and of BlackLight Power, Inc. (n/k/a Brilliant Light Electrical power, Inc. ), a power research company, from 2009 until the year of 2010. Mr. Barry retains a B. The. from Pennsylvania Express University.

About Meters. Kathleen Behrens Wilsey, Ph. D.
Dr . Behrens Wilsey offered as a member of the panel of directors of each of Sarepta Therapeutics, Inc. (SRPT), a multi-billion dollar healthcare research and medicine development company focused within the discovery plus advancement unique RNA-targeted therapeutics for typically the treatment of unusual neuromuscular diseases, given that March 2009 (Chairwoman of the Table since April 2015) and IGM Biosciences, Inc., an independently held biotechnology organization, since January 2019. Dr. Behrens Wilsey has worked as a possible independent life sciences consultant and entrepreneur since December 2009. She served because the Co-Founder, President, Ceo and as the director of the KEW Group Incorporation., a private oncology services company, coming from January 2012 right up until June 2014. Before in her career, Dr. Behrens Wilsey served as the general partner intended for selected venture finances for RS Assets, a mutual finance firm, from 1996 until December this year. While Dr. Behrens Wilsey worked from RS Investments, through 1996 to 2002, she served seeing that a managing director at the company and, from 2003 to December yr, she served as being a consultant to the particular firm. During of which time, Doctor Behrens Wilsey also offered as a member from the President's Council of Advisors in Science and Technological innovation (PCAST), from i b?rjan p? tv?tusentalet to 2009 plus as chairwoman of PCAST's Subcommittee on Personalized Medicine, while well as the President, director in addition to chairwoman from the National Venture Capital Association, an organization that will advocates for community policy that works with the American Entrepreneurial ecosystem, from 93 until 2000. Former to that, your woman served as being a total partner and controlling director for Robertson Stephens & Corp., an investment business, from 1983 via 1996. She served as a movie director of Amylin Pharmaceutical drugs, Inc. (formerly AMLN), a biopharmaceutical firm, from 2009 right up until the company's selling in 2012 to Bristol-Myers Squibb Co. Prior to that, she served in the board associated with directors Abgenix, Inc. (formerly ABGX), the biopharmaceutical company, from 2001 until the company was acquired by Amgen, Inc. in 2006. Coming from 1997 to 2005, Dr. Behrens was a director with the Board on Technology, Technology and Economic Policy for typically the National Research Council. Dr . Behrens Wilsey was also a Co-Founder from the Coalition with regard to modern world Medicine, some sort of trade association with regard to new generation acte companies. Doctor Behrens Wilsey holds the B. S. throughout Biology and a Ph level. D. in Microbiology from the College or university of California, Davis.

About James D. Bierman
Mr. Bierman served as Chief executive and Chief Exec Officer of Owens & Minor, Incorporation., a Fortune five-hundred company and the leading distributor regarding as well as surgical products, from September 2014 to June 2015. Previously, he offered in numerous other senior citizen roles at Owens & Minor, including President and Chief Operating Officer from August 2013 to September 2014, Professional Vice President and Chief Operating Officer through March 2012 to August 2013, Professional Vp and Chief Financial Officer by April 2011 to be able to March 2012, plus Senior Vice Leader and Chief Monetary Officer from August 2007 to 04 2011. From 2001 to 2004, Mister. Bierman served while Executive Vp plus Chief Financial Police officer at Quintiles Transnational Corp. Ahead of joining Quintiles Transnational, Mister. Bierman was a lover at Arthur Andersen LLP. Mr. Bierman currently serves in the board regarding directors of Tenet Healthcare Corporation (THC) and previously served on the panels of directors associated with Owens & Small, Inc. (OMI) plus Team Health Loge, Inc. (formerly TMH). Mr. Bierman attained his B. Some sort of. from Dickinson College or university wonderful M. M. A. at Cornell University's Johnson Scholar School of Administration.

About K. John Newton
Mr. Newton has, since 2014, served as Key Executive Officer and also a member of the board of directors of Apollo Endosurgery, Inc. (APEN), a leader in the field of stomach therapeutic endoscopy. From 2009 to 2014, Mr. Newton dished up as Executive Perversité President and Primary Financial Officer at ArthroCare Corporation (ARTC), a medical system company, including from 2013 as Chief Operating Officer. Prior to his leadership at ArthroCare, Mr. Newton served in a number of business officer roles, which include President and Chief Executive Officer, at Synenco Energy, Inc., a Canadian oil sands organization. From 1994 to be able to 2004, Mr. Newton was a Spouse at Deloitte & Touche LLP. Mister. Newton holds a B. B. Some sort of. in accounting coming from the University associated with Texas at San Antonio.

About Timothy R. Wright
Mr. Wright became MiMedx's Chief Executive Expert, effective as of May 13, 2019. Previously, Mr. Wright served being a Spouse at Signal Mountain Advisors, LLC, a new consulting practice, due to the fact February 2011. Mister. Wright served while President and Key Executive Officer involving M2Gen Corp., a privately held cancer and wellness informatics company, involving July 2017 and September 2018. Just before M2Gen Corp., Mister. Wright served seeing that Executive Vice Leader, Mergers and Acquisitions, Strategy and Development for Teva Pharmaceutic Industries Ltd. ("Teva"), a pharmaceutical business specializing in generic drugs, from April 2015 until August 2017. Before Teva, Mister. Wright was typically the founding partner involving The Ohio Point out University Comprehensive Tumor Drug Development Company. Mr. Wright in addition served as Chairman, Interim Chief Executive Officer and a representative of Curaxis Pharmaceutic Corporation ("Curaxis"), a new pharmaceutical company specialized in in the growth of drugs for the treatment associated with Alzheimer's disease plus various cancers, from July 2011 in order to July 2012. Curaxis had been experiencing economical difficulties prior in order to Mr. Wright's period and, because of this, the particular company filed intended for Chapter 11 individual bankruptcy in July 2012. Mr. Wright has been a director of Agenus, Inc. (Nasdaq: AGEN), an immune oncology company, since 2006 and its prospect director since year. Mr. Wright furthermore serves as Chairperson associated with The Ohio Express University Comprehensive Malignancy Center Drug Advancement Institute, serves as director of The Kentkucky State Innovation Foundation and sits within the Ohio State College College of Drug-store Dean's Corporate Council. Mr. Wright received a Bachelor's of Science in Advertising and marketing from The Iowa State University.

Concerning MiMedx
MiMedx� is certainly an industry chief in advanced twisted care and an emerging therapeutic biologics company developing in addition to distributing human placental tissue allografts using patent-protected processes with regard to multiple sectors of healthcare. The corporation processes the human placental tissue utilizing its proprietary PURION� process methodology, among some other processes, to produce allografts by making use of aseptic processing approaches in addition in order to terminal sterilization. MiMedx has supplied over 1 . 5 trillion allografts to time frame. For additional info, please visit www.mimedx.com.

About Prescience Stage Capital Management
Supposition Point Capital Management is a private expense manager that engages forensic investigative strategies to unearth significant mispricings in international markets. It has specialized in extensive research of difficult-to-analyze public companies in order to uncover substantial elements of the organization that have been overlooked or overlooked by others.

Prescience Point manages personal funds on behalf of the clients and rules of sciene and takes jobs both long plus short for the research. Prescience Level invests across a broad set regarding equities that that believes have abnormally large disparities involving what their hidden businesses are intrinsically worth and just what their securities offer for. The company was founded by simply investor Eiad Asbahi in 2009 and even is headquartered inside of Baton Rouge, ARE GENERALLY. Prescience Point Money Management is a listed investment advisor with the State of Louisiana. Follow @PresciencePoint.

Safe Harbor Statement

This press release includes forward-looking assertions, including statements with regards to the plan of MiMedx Group, Incorporation. (the "Company") to be able to refresh the Board, the effects of such refreshment on the Company and expectations regarding Table leadership. Forward-looking transactions may be recognized by words such as "believe, " "expect, " "may, inches "plan, " "potential, " "will, very well "would" and similar expressions and are generally based on current beliefs and expectations. Forward-looking statements are subject to risks and even uncertainties, as well as the Company cautions investors against placing undue dependence on such claims.

Actual results may differ materially by those set out within the forward-looking claims resulting from various components, like the results associated with any election regarding Class II or even Class III directors. There is little assurance the Board's nominees will probably be elected at the Industry’s 2018 annual conference of shareholders (the "2018 Annual Meeting") or the Carrier's 2019 annual getting together with of shareholders. Virtually any forward-looking statements communicate only as involving the date regarding this press discharge, and except because required by rules, the Company presumes no obligation to be able to update any forward-looking statement, whether resulting from new information, foreseeable future events or otherwise.

Information
The Firm intends arranging a new definitive proxy statement and associated GLOWING BLUE proxy card inside connection with the solicitation of proxies for your 2018 Yearly Meeting with the Investments and Exchange Commission payment (the "SEC"). Particulars about the nominees of the Company's table of directors intended for election with the 2018 Annual Meeting will be included inside of the proxy statement. BEFORE MAKING ANY KIND OF VOTING DECISION, INVESTORS OF THE COMPANY ARE URGED TO BE ABLE TO READ ALL APPROPRIATE DOCUMENTS FILED WITH OR FURNISHED IN ORDER TO THE SEC, LIKE THE COMPANY'S DEFINITIVE WEB PROXY STATEMENT AND ANY SUPPLEMENTS THERETO, SIMPLY BECAUSE THEY WILL CONTAIN INFORMATION AND FACTS. Investors and shareholders will be able to obtain a copy of the particular definitive proxy declaration and other documents filed by the particular Company free regarding charge from typically the SEC's website at www.sec.gov. The Carrier's shareholders is likewise able to obtain, at no cost, a copy involving the definitive web proxy statement as well as other related filed documents coming from the "SEC Filings" section of the particular Company's website with www.mimedx.com.

prescience point of the Solicitation
The corporation, its directors, it is director nominees and certain of their executive officers are really participants in the solicitation of proxies from shareholders in respect of the particular 2018 Annual Gathering. Information regarding the names from the Company's directors, director candidates and executive representatives and their respective interests in typically the Company by safety holdings or normally is set on in the Carrier's Current Report about Form 8-K recorded using the SEC about May 30, 2019. Additional information about the interests of these types of participants in virtually any proxy solicitation and even a description of these direct and roundabout interests, by protection holdings or otherwise, will also be included in any web proxy statement as well as other pertinent materials to become submitted with the SEC, if and if they become accessible.
Here's my website: https://pbase.com/egebergperkins34/root